De Novo device
Sensimed Triggerfish
Sensimed AG · Ocular Pattern Recorder (PLZ, Class II) · First FDA decision Mar 4, 2016, newest Mar 4, 2016Glaucoma
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
De Novo pathway
Device trials
38
Naming "Sensimed Triggerfish"
MAUDE reports
0
Brand "Sensimed Triggerfish", since 2015
PubMed studies
37
Mentioning "Sensimed Triggerfish"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Sensimed Triggerfish
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 0 of 1 decisions filed under this name.
FDA's records could not be loaded.
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Sensimed Triggerfish", any status and sponsor, newest update first.
Sensimed AGNot on our public-company list
NCT03047239 · 0 participants · Start Jun 1, 2023 · Primary completion Jun 1, 2023
Device: SENSIMED Triggerfish · For: Open Angle Glaucoma
Faculty Hospital Kralovske VinohradyGovernment (non-federal)
NCT06016712 · 9 participants (planned) · Start Aug 8, 2023 · Primary completion Dec 31, 2025
Device: SENSIMED Triggerfish Eye Lenses · For: Intraocular Pressure; Delivery
Sites: Prague, Czechia
Fundacio Privada Mon Clinic BarcelonaAcademic, hospital or other
NCT06607705 · 53 participants (planned) · Start Oct 21, 2024 · Primary completion Oct 1, 2025
Device: Monitoring with contact lens sensor; Monitoring with contact lens sensor and 1 more · For: Glaucoma Eye
Sites: Barcelona, Spain · 2 sites in all
35 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Sensimed Triggerfish", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code PLZ
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Sensimed Triggerfish"[tiab]. The summary above synthesizes these.
- Efficacy of the SENSIMED Triggerfish® in the postoperative follow-up of PHACO-ExPRESS combined surgery.
Osorio-Alayo V, Pérez-Torregrosa VT, Clemente-Tomás R, et al. · Arch Soc Esp Oftalmol · 2017Observational Study
- What happens to glaucoma patients during sleep?
Aref AA · Curr Opin Ophthalmol · 2013Review
- Comparison of SENSIMED Triggerfish® (TF) 24-Hour Monitoring in Open-Angle Glaucoma Patients Before and After Trabeculectomy.
Beck A, Uhrig M, Schuster A, et al. · J Clin Med · 2025
- Can the SENSIMED Triggerfish® lens data be used as an accurate measure of intraocular pressure?
Vitish-Sharma P, Acheson AG, Stead R, et al. · Acta Ophthalmol · 2018
- The Sensimed Triggerfish contact lens sensor: efficacy, safety, and patient perspectives.
Dunbar GE, Shen BY, Aref AA · Clin Ophthalmol · 2017Review
- Association of Ultra-Short-Term Intraocular Pressure Fluctuation With Disease Progression in Primary Angle Closure Glaucoma: The CUPAL Study.
Tan S, Yu M, Baig N, et al. · J Glaucoma · 2022Research Support, U.S. Gov't, Non-P.H.S.
- Advances and Challenges in Wearable Glaucoma Diagnostics and Therapeutics.
Shean R, Yu N, Guntipally S, et al. · Bioengineering (Basel) · 2024Review
- [Contemporary possibilities of intraocular pressure measurement].
Hornová J, Baxant A · Cesk Slov Oftalmol · 2013Review
- Continuous 24-hour intraocular pressure monitoring for glaucoma--time for a paradigm change.
Mansouri K, Weinreb R · Swiss Med Wkly · 2012Research Support, Non-U.S. Gov't, Review
- Assessing Efficacy of Canaloplasty Using Continuous 24-Hour Monitoring of Ocular Dimensional Changes.
Rekas M, Danielewska ME, Byszewska A, et al. · Invest Ophthalmol Vis Sci · 2016
- Evaluation of the 24-hour intraocular pressure and systemic blood pressure at the same time.
Karadag R, Koyun E, Ozsoy I, et al. · J Fr Ophtalmol · 2019Evaluation Study
- Circadian Intraocular Pressure Fluctuation and Disease Progression in Primary Angle Closure Glaucoma.
Tan S, Yu M, Baig N, et al. · Invest Ophthalmol Vis Sci · 2015Research Support, Non-U.S. Gov't
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.